Oculis Acquires Privosegtor Rights in $3.8M Deal to Strengthen Neuro-Ophthalmology Lead
Event summary
- Oculis to acquire global rights to Privosegtor (ACT-01) and ACT-02 from Accure Therapeutics for $3.8M upfront cash plus up to 2,050,000 Oculis shares.
- Transaction terminates existing license agreement, eliminating milestone payments and royalties for Oculis.
- Closing for Privosegtor expected by February 28, 2027; ACT-02 closing dependent on Privosegtor deal completion.
- Privosegtor is in PIONEER-1 registrational trial for optic neuritis with IND submission for acute MS relapse planned Q4 2026.
The big picture
This acquisition consolidates Oculis' control over Privosegtor's development, removing financial encumbrances from the original license agreement. The move aligns with a broader industry trend of biopharmaceutical companies verticalizing asset control to maximize valuation ahead of potential partnerships or exits. With Privosegtor holding Breakthrough Therapy and PRIME designations, Oculis positions itself as a key player in neuro-ophthalmology, where therapeutic options remain limited.
What we're watching
- Regulatory Momentum
- Whether Privosegtor's PIONEER program can maintain current trial pace through 2027 closings.
- Valuation Dynamics
- How Oculis' share issuance (up to 2,050,000 shares) impacts investor perception of Privosegtor's potential.
- Pipeline Expansion
- The pace at which ACT-02 advances from preclinical stage under Oculis' ownership.